Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004

(2009) Ulrike Bacher et al.   ANNALS OF HEMATOLOGY

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2009) Seok Lee et al.   CANCER

Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia

(2008) M. Mohty et al.   BLOOD

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

(2008) S. J. Lee et al.   BLOOD

Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia

(2008) Jerzy Holowiecki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of chronic myeloid leukemia in blast crisis

(2008) R. Hehlmann et al.   HAEMATOLOGICA

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

(2008) F. Palandri et al.   HAEMATOLOGICA

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

(2008) A Shimoni et al.   LEUKEMIA

KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients

(2008) Arnold van der Meer et al.   MOLECULAR IMMUNOLOGY